Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Dec;70(12):4400-4404.
doi: 10.4103/ijo.IJO_679_22.

Role of 0.01% atropine in high myopic children of Moradabad, India (RAMCOM Study)

Pradeep Agarwal  1 , Ashi Khurana  2 , Veenu Maan  1 , Samir Sutar  3 , Lokesh Chauhan  4
Affiliations
Clinical Trial

Role of 0.01% atropine in high myopic children of Moradabad, India (RAMCOM Study)

Pradeep Agarwal et al. Indian J Ophthalmol. 2022 Dec.

Abstract

Purpose: Low-concentration atropine is an emerging therapy for myopia progression, but its efficacy remains uncertain among high myopic children. This study aimed to evaluate the efficacy and safety of low-concentration atropine eye drop (0.01%) in high myopic children.

Methods: A non-randomized, parallel-group, longitudinal interventional cohort study. Myopic children were divided into two groups: (1) the intervention arm of children who received one drop of topical 0.01% atropine once a day at bedtime and (2) the control arm, in which enrolled children who were on observation only. Repeated measurements of spherical equivalent refractive errors (SERs) were performed at baseline and 1 and 2 years after treatment.

Results: A total of 37 eyes were enrolled in the intervention arm (allocated to 0.01% atropine at year 1 follow-up) and 23 eyes in the control arm. After 1 year of 0.01% atropine therapy, the myopia progression was 0.15 ± 0.9 D in the intervention group versus 1.1 ± 1 D in the control group (P = 0.001). Similarly, after 2 years of treatment, the myopia progression was 0.3 ± 1.1 D in the intervention group versus 1.4 ± 1.1 D in the control group (P ≤ 0.001).

Conclusion: Compared to no treatment, 0.01% atropine treatment had shown better effect on myopia progression in high myopic children.

Keywords: 0.01% atropine; efficacy; high myopia; myopia progression; safety.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Myopia progression from baseline to Y1, Y2, and Y3
Figure 2
Figure 2
Myopia progression at different time points
Figure 3
Figure 3
Comparison of myopia progression between the intervention and control groups
See this image and copyright information in PMC

References

    1. Wu PC, Chuang MN, Choi J, Chen H, Wu G, Ohno-Matsui K, et al. Update in myopia and treatment strategy of atropine use in myopia control. Eye (Lond) 2019;33:3–13. - PMC - PubMed
    1. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123:1036–42. - PubMed
    1. The impact of myopia and high myopia. WHO report myopia. 2016. [Last assessed on 2022 Nov 11]. Available from: https://www.iapb.org/learn/resources/the-impact-of-myopia-and-high-myopia/
    1. Ikuno Y. Overview of the complications of high myopia. Retina. 2017;37:2347–51. - PubMed
    1. Saxena R, Vashist P, Menon V. Is myopia a public health problem in India? Indian J Community Med. 2013;38:83–5. - PMC - PubMed

Publication types